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Treatment-resistant depression and peripheral
C-reactive protein
Samuel R. Chamberlain, Jonathan Cavanagh, Peter de Boer, Valeria Mondelli, Declan N.C. Jones,
Wayne C. Drevets, Philip J. Cowen, Neil A. Harrison, Linda Pointon, Carmine M. Pariante* and
Edward T. Bullmore*†
Background
C-reactive protein (CRP) is a candidate biomarker for major
depressive disorder (MDD), but it is unclear how peripheral CRP
levels relate to the heterogeneous clinical phenotypes of the
disorder.
Aim
To explore CRP in MDD and its phenotypic associations.
Method
We recruited 102 treatment-resistant patients with MDD
currently experiencing depression, 48 treatment-responsive
patients with MDD not currently experiencing depression,
48 patients with depression who were not receiving medication
and 54 healthy volunteers. High-sensitivity CRP in peripheral
venous blood, body mass index (BMI) and questionnaire
assessments of depression, anxiety and childhood trauma were
measured. Group differences in CRP were estimated, and partial
least squares (PLS) analysis explored the relationships between
CRP and specific clinical phenotypes.
Results
Compared with healthy volunteers, BMI-corrected CRP was sig-
nificantly elevated in the treatment-resistant group (P = 0.007;
Cohen’s d = 0.47); but not significantly so in the treatment-
responsive (d = 0.29) and untreated (d = 0.18) groups. PLS yielded
an optimal two-factor solution that accounted for 34.7% of vari-
ation in clinical measures and for 36.0% of variation in CRP.
Clinical phenotypes most strongly associated with CRP and
heavily weighted on the first PLS component were vegetative
depressive symptoms, BMI, state anxiety and feeling unloved as
a child or wishing for a different childhood.
Conclusions
CRP was elevated in patients with MDD, and more so in treat-
ment-resistant patients. Other phenotypes associated with ele-
vated CRP included childhood adversity and specific depressive
and anxious symptoms. We suggest that patients with MDD
stratified for proinflammatory biomarkers, like CRP, have a dis-
tinctive clinical profile that might be responsive to second-line
treatment with anti-inflammatory drugs.
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Immunological mechanisms are increasingly implicated in the
pathogenesis of depressive symptoms.1–3 Activation of the periph-
eral immune system has been consistently associated with major
depressive disorder (MDD).4–8 However, it has also been antici-
pated that not all patients with MDD will be peripherally inflamed
to the same extent. A deeper understanding of how peripheral
immune biomarkers relate to some of the dimensions of clinical het-
erogeneity encompassed by a diagnosis of MDD could be an
important step towards mechanistically stratified treatment of
depression in the future.3,9,10
C-reactive protein (CRP) is an acute-phase protein that is
widely used in clinical practice and has also been measured in
many prior studies of MDD.8 A high-sensitivity assay for CRP is
well-validated and accessible. CRP synthesis is induced in the
liver by proinflammatory cytokines – especially interleukin 6 (IL-
6) – in response to infection, inflammation and tissue damage. In
a meta-analysis of 20 case–control studies,8 CRP was moderately
increased ‘on average’ (Cohen’s d = 0.47) in patients with MDD.
However, there was significant heterogeneity of effect size
between studies that may be attributable to clinical heterogeneity,
with higher CRP in severe depression (Cohen’s d = 0.50) than in
mild/moderate depression (Cohen’s d = 0.37), as well as methodo-
logical differences between studies.11
We were motivated to test the hypothesis that the clinically
defined subgroup of patients with treatment-resistant depression
would have the most abnormally increased CRP. An association
between treatment resistance to monoaminergic antidepressant
drugs and increased CRP is hypothetically predictable on clinical
and mechanistic grounds. Clinical studies indicate that proinflam-
matory cytokines that induce CRP synthesis are increased in treat-
ment-resistant MDD.12,13 Mechanistic studies have shown that
proinflammatory cytokines can reduce the extracellular availability
of serotonin by biasing expression of genes related to serotonin trans-
port and tryptophan metabolism.14,15 Single studies have also
reported that elevated CRP may be associated with other dimensions
of clinical heterogeneity, namely atypical depression,16 childhood
adversity,17 higher numbers of previous depressive episodes18 or
anxiety in male patients.19
We measured CRP in four groups of participants: patients with
MDDwho are currently experiencing depression but are not receiv-
ing medication (untreated), patients who are currently depressed
and are receiving medication (treatment-resistant), patients who
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are currently receiving medication but are not depressed (treat-
ment-responsive) and healthy volunteers with no history of MDD
or monoaminergic drug treatment. The primary hypothesis, that
CRP would be most clearly increased above normal levels in treat-
ment-resistant patients with MDD, was tested by planned analyses
of between-group differences in mean CRP. In a secondary analysis,
we took a more exploratory approach to the question of what other
dimensions of clinical heterogeneity in the sample might be related
to variation in CRP. We used the multivariate technique of partial
least squares (PLS) to explore the relationships between CRP and
multiple (139) clinical phenotypes – ranging from body mass
index (BMI) to questionnaire items for depressive symptoms,
anxiety states or history of childhood adversity.20–23 In this way,
we could identify a subset of clinical phenotypes weighted strongly
on latent dimensions of clinical heterogeneity that were predictive of
higher CRP levels. We also tested the confirmatory hypothesis that
scores on these clinical dimensions of peripheral inflammation
would be higher in the subgroup of patients with treatment resist-
ance defined a priori.
Method
This was a non-interventional study, conducted as part of the
Wellcome Trust Consortium for Neuroimmunology of Mood
Disorders and Alzheimer’s disease (NIMA). There were five clinical
study centres in the UK: Brighton, Cambridge, Glasgow, King’s
College London and Oxford. All procedures were approved by an
independent research ethics committee (National Research Ethics
Service East of England, Cambridge Central, UK; approval
number 15/EE/0092) and the study was conducted according to
the Declaration of Helsinki. All participants provided informed
consent in writing and received £100 compensation for taking part.
Sample and eligibility criteria
We recruited four groups of participants, those with treatment-
resistant depression, treatment-responsive depression, untreated
depression and healthy volunteers.
For all participants, the following inclusion criteria applied: age
25–50 years; able to give informed consent; able to fast for 8 h and
abstain from strenuous exercise for 72 h prior to venous blood sam-
pling; and fluent English. The following exclusion criteria applied:
pregnancy or breast feeding, alcohol or substance use disorder in
the preceding 12 months, participation in an investigational drug
study within the preceding 12 months, lifetime history of any
medical disorder or current use of any medication (e.g. statins, cor-
ticosteroids, antihistamines, anti-inflammatory medications) likely
to compromise interpretation of CRP (see Supplementary
Material, available at https://doi.org/10.1192/bjp.2018.66).
Adult patients meeting DSM-5 criteria for MDD24 were
recruited from National Health Service mental health and primary
care services and from the general population by purposive adver-
tising. Lifetime histories of bipolar disorder or non-affective psych-
osis were additional exclusion criteria. Diagnosis of MDD and other
psychiatric disorders was ascertained by the Structured Clinical
Interview for DSM-5.25 Current depressive symptom severity was
defined by total scores from the 17-item Hamilton Rating Scale
for Depression (HAM-D),26 and lifetime antidepressant medication
use was quantified by the Antidepressant Treatment Response
Questionnaire (ATRQ).27 The ATRQ was completed by a mem-
ber of the study team via an interview with each participant. This
structured instrument records all medications received for at least
6 weeks for treatment of depression, for current and past depressive
episodes. For each medication ever received, the percentage
improvement experienced by the participant during the correspond-
ing episode was documented (<25%, 25–49% improved, 50–75%
improved or >75% improved). Treatment response was conserva-
tively defined as >75% improvement in depressive symptoms, as
recalled by the participant. The ATRQ provides definitions for the
minimum dose for each medication to be considered an adequate
treatment course.27
Patients were assigned to one of three subgroups or strata, per
protocol: treatment-resistant (DEP+MED+) patients who had
total HAM-D score > 13 and had been medicated with a monoami-
nergic drug at a therapeutic dose for at least 6 weeks; treatment-
responsive (DEP−MED+) patients who had total HAM-D score
< 7 and had been medicated with a monoaminergic drug at a thera-
peutic dose for at least 6 weeks; and untreated (DEP+MED−)
patients who had HAM-D score > 17 and had not been medicated
with a monoaminergic drug for at least 6 weeks. Cut-offs were
defined a priori based on the literature. Total HAM-D score >17
is a standard threshold for entry into placebo-controlled treat-
ment trials of MDD, whereas a lower threshold of total HAM-D
score > 13 is typically used to define treatment-resistant depression,
because there is usually some modest symptomatic response to
treatment even if patients remain depressed.28,29
A group of healthy volunteers was recruited by advertising with
no current or past history of any major psychiatric disorder as
defined by DSM-5, and no history of monoaminergic drug treat-
ment for any indication. Healthy volunteers completed the same
screening and baseline assessments as patient groups (see below).
Age, gender, medical history, smoking status and family history
were documented by semi-structured clinical interviews. Height
and weight were measured for calculation of BMI (kg/m2).
Questionnaire assessments
Psychological symptoms and childhood adversity were assessed by
administration of the following questionnaires (see Supplementary
Material): the Beck Depression Inventory (BDI v2.030), the
Spielberger State-Trait Anxiety Rating scale (STAI31), the Chalder
Fatigue Score (CFS32), the Snaith-Hamilton Pleasure Scale
(SHAPS33) and the Childhood Trauma Questionnaire (CTQ34).
High-sensitivity CRP measurement
CRP was measured as one of many immunological markers in a
venous blood sample drawn from each participant. Here, we focus
on CRP because this has established utility as an immune biomarker
of depression, having been widely used in case–control and epi-
demiological studies, and thus informing our hypothesis that CRP
would be increased specifically in treatment-resistant depression.
Participants fasted for 8 h and abstained from strenuous exercise
for 72 h prior to venous blood sampling between 08:00 and 10:00.
Patients taking psychotropic medication(s) continued their usual
medication during the assessment day. High-sensitivity CRP was
assayed via a central laboratory (see Supplementary Material).
Statistical analysis
For analysis of between-group differences in high-sensitivity CRP
and other variables, we first compared all participants with MDD
to healthy volunteers, using planned t-tests. We then evaluated pair-
wise group differences with post hoc t-tests, provided the main effect
of group was significant by one-way analysis of variance. When
assumptions of normality were violated, data were appropriately
transformed and/or non-parametric tests were used for inference.
Cohen’s d was reported for the effect size of high-sensitivity CRP
corrected for BMI in each clinical group compared with healthy
volunteers. Additionally, we compared the proportion of
Chamberlain et al
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participants in each group who had clinically elevated CRP, defined
as >3 mg/L.35,36 The threshold for statistical significance was
defined as two-tailed P < 0.05 throughout.
To identify demographic and clinical phenotypes associated with
variation in CRP across all study participants, we utilised the method
of PLS, as implemented in JMP Pro software version 13.0.37 PLS is a
multivariate technique for modelling relationships between a set of
predictor (X) and response (Y) variables in terms of a set of mutually
orthogonal latent factors, or PLS components.21,22,38,39 It requires no
distributional assumptions and thus is robust against skewness. This
same software was also used for other statistical tests and generation
of violin plots for CRP across groups.
Here we modelled high-sensitivity CRP as the response variable,
Y. The predictor variables, X, comprised gender, age, BMI, and educa-
tion level as well as each of the 21 HAM-D, 11 CFS, 21 BDI, 28 CTQ,
40 STAI and 14 SHAPS questionnaire items. Data from all partici-
pants were included and missing data were imputed by sample
means. Thus, the Y vector was (252 × 1) and the X matrix was
(252 × 139). Because of the number of variables and the expectation
that many variables would correlate with each other, other statistical
approaches (such as linear regression) would not have been valid. In
contrast, PLS is an ideal statistical technique under these circum-
stances.21,22,38,39 An initial PLSmodel was fitted including all predictor
variables. We then used a two-step approach to identify the subset of
predictor variables that significantly contributed to themodel: first, we
discarded individual X variables with low importance by conventional
criteria (variable importance parameter < 0.8 and standardised abso-
lute model coefficient less than the absolute magnitude of 0.0540);
second, we utilised a more conservative approach of excluding vari-
ables whose standardisedmodel coefficient had a 95%CI (constructed
by bootstrapping the data 1000 times) that included zero. PLS models
were fitted by leave-one-out cross-validation (non-linear iterative PLS
(NIPALS) algorithm), and the optimal number of latent factors was
selected by minimising the predictive residual sum of the squares.
The statistical significance of the final model was confirmed by com-
paring the percentage of variation in X and Y accounted for in the
experimental data compared with the null distributions of the percent-
age of X or Y variance sampled by bootstrapping (1000 iterations).
Results
Demographic and clinical data
The size of each group and their demographic and clinical charac-
teristics are summarised in Table 1. The groups did not differ sig-
nificantly in terms of demographic characteristics. As expected,
post hoc tests indicated that each group differed significantly from
each other group on HAM-D total score (least significant t = 4.19,
d.f. = 248, P < 0.001). The mean number of failed pharmacological
treatments for MDD episodes (<75% symptomatic response,
defined by ATRQ) is listed for each clinical group in Table 1. The
treatment-resistant group had more failed treatments than the
untreated group (Wilcoxon Z = 2.843, P = 0.005); both the treat-
ment-resistant group and the untreated group had significantly
more failed treatments than the treatment-responsive group
(Wilcoxon Z = 5.794, P < 0.001 and Wilcoxon Z = 3.079, P = 0.002,
respectively). The majority of treatment-resistant patients were
taking selective serotonin reuptake inhibitors (see Table 1 footnote).
Summary statistics for questionnaire-based measures and comorbid-
ities are provided in supplementary Tables 1 and 2.
CRP
Mean high-sensitivity CRP concentrations (and 95% CIs) are shown
in Table 1. Mean CRP was significantly increased in all patients with
MDD compared with healthy controls (Wilcoxon Z = 2.7, P = 0.007).
Both treatment-resistant and treatment-responsive groups had
significantly higher mean high-sensitivity CRP than controls
(Wilcoxon Z = 2.9, P = 0.004 and Wilcoxon Z = 2.6, P = 0.010,
respectively). Across all patients with MDD, drug treatment class
did not significantly affect CRP levels (F = 0.799, P = 0.572), nor
did the number of failed treatments in the past (F = 0.245, P = 0.621).
The proportion of participants with high-sensitivity CRP levels
exceeding the conventional threshold value of 3 mg/L was also
significantly different between the pooled MDD groups and con-
trols (likelihood ratio χ2 = 10.01, P = 0.002). Treatment-resistant,
untreated and treatment-responsive MDD groups all had signifi-
cantly increased proportions of participants with high-sensitivity
CRP > 3 mg/L compared with healthy volunteers (likelihood ratio
χ2 = 8.4, P = 0.004; likelihood ratio χ2 = 8.6, P = 0.003; and likeli-
hood ratio χ2 = 5.0, P = 0.025, respectively). No other post hoc test
was statistically significant; that is, depressed groups did not differ
significantly from each other (all P > 0.09).
Log-transformed and BMI-corrected CRP
The distributions of high-sensitivity CRP were positively skewed
(moment skewness: 5.08)41 and therefore were normalised by base
log10 transform (see Fig. 1). Log10 CRP was significantly increased
in all patients with MDD compared with controls (t = 2.81, d.f. =
250, P = 0.004). Only treatment-resistant and treatment-responsive
patients had significantly higher log10 CRP than controls (t = 3.07,
d.f. = 248, P = 0.002 and t = 2.32, d.f. = 248, P = 0.021, respectively).
As anticipated by prior studies,42–44 there was a significant posi-
tive correlation between BMI and log10 CRP across all study parti-
cipants (Spearman’s rho = 0.56, d.f. = 250, P < 0.001; Fig. 1). Because
BMI data were also positively skewed (moment skewness: 1.03),41
we regressed log10 CRP on log10 BMI and used the residuals as esti-
mates of BMI-corrected CRP (Fig. 1). BMI-corrected CRP was sig-
nificantly elevated in all patients withMDD compared with controls
(t = 2.24, d.f. = 238, P = 0.026). Post hoc t-tests indicated that only
the treatment-resistant patients had significantly higher mean
BMI-corrected CRP than the controls (t = 2.71, d.f. = 236, P =
0.007; Cohen’s d = 0.47).
To assess the possible confounding effect of symptom severity,
we identified the subgroup of treatment-resistant patients (n = 48)
that had a total HAM-D score > 17, thereby corresponding to the
cut-off used to define the untreated group. We confirmed that
BMI-corrected CRP was abnormally increased in treatment-resist-
ant patients with HAM-D > 17 (t = 3.0, P = 0.004) with a case–
control difference of similar size (Cohen’s d = 0.43) to that of treat-
ment-resistant patients with HAM-D > 13.
PLS analysis of the relationship between CRP and
clinical variables
A total of 13 out of 139 clinical phenotypes passed criterion for an
important effect on CRP levels. Iterative cross-validation of the PLS
model including only these important variables yielded an optimal
two-factor solution (Fig. 2 and Supplementary Fig. 2), which
accounted in total for 34.7% of variation in clinical measures (X),
and for 36.1% of variation in CRP (Y). This differed significantly
from the proportions of variance expected under the null hypothesis
(percentage variance (X) = 12.3%, 95% CI 12.1–12.5%; percentage
variance (Y) = 2.7%, 95% CI 1.9–3.0%).
The first PLS component (PLS1) accounted for 26.7% of the
variation in high-sensitivity CRP. Positive scores on PLS1 indicated
higher CRP. The clinical phenotypes that were significantly
weighted on PLS1 were higher BMI, not feeling loved in childhood
(CTQ item seven), not feeling calm (STAI item one), wanting to
change one’s family in childhood (CTQ item ten), psychomotor
Treatment-resistant depression and inflammation
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retardation (HAM-D item eight), middle insomnia (HAM-D item
five) and not being able to work (BDI item 15). The PLS1 scores
for individual participants differed significantly between groups
(F = 19.88, d.f. = 3248, P < 0.001; Fig. 2). PLS1 scores were highest
in the treatment-resistant group, followed by the untreated group,
the treatment-responsive group and the healthy volunteers.
The second PLS component (PLS2) orthogonally explained
9.4% of variation in CRP. PLS scores in each group, and variables
loading significantly onto PLS2, are summarised in Supplementary
Fig. 3. Positive scores on PLS 2 indicated lower CRP. PLS2 scores dif-
fered significantly between groups (F = 24.34, d.f. = 3248, P < 0.001).
Untreated patients had the highest PLS2 scores, followed by treat-
ment-resistant patients, treatment-responsive patients and healthy
volunteers.
Discussion
This is the first study to measure peripheral CRP with the same
high-sensitivity assay across a large sample of patients with MDD
(n = 198) prospectively stratified in terms of their current and
past history of treatment with monoaminergic antidepressant
drugs.We replicated the well-established finding that CRP is signifi-
cantly increased ‘on average’ in patients with MDD, screened for
physical comorbidity, and compared with healthy volunteers who
did not differ in terms of age, gender, BMI and cigarette smoking
status. However, we also found some evidence for our primary
hypothesis that CRP was most increased in the subgroup of patients
with treatment-resistant depression (n = 102). The standardised size
of the case–control difference in CRP between healthy volunteers
and treatment-resistant patients (Cohen’s d = 0.47) was higher
than the case–control difference for treatment-responsive (0.29)
or untreated patients (0.18). Controlling for non-normality of the
CRP distribution, and for the strong positive correlation between
CRP and obesity, we found that the case–control difference in
CRP remained significant only for the subgroup of treatment-
resistant patients. These results of planned analysis are consistent
with the hypothesis that peripheral inflammation is a marker or
risk factor for treatment-resistant depression. It should be noted
that CRP was somewhat elevated even in treatment-responsive
patients, suggesting that a degree of elevated CRP could be trait-
related rather than related to current symptoms or treatment status.
Taking a convergent but more exploratory approach to the data,
we used multivariate analysis to identify two dimensions of clinical
heterogeneity that were predictive of CRP. We found that a subset
of clinically measured phenotypes explained approximately 36% of
the variance in CRP. High BMI, high scores on vegetative symptoms
of depression, low scores on calmness and a history of childhood
adversity were all predictive of increased CRP. As expected from the
results of our primary analysis, we confirmed that the group of patients
defined a priori in terms of treatment resistance had the highest scores
on this clinical profile associated with high-sensitivity CRP.
Treatment-resistant depression and peripheral
inflammation
Monoamine reuptake inhibitors and related drugs are evidence-based
pharmacological treatments for MDD, but response failure afflicts
approximately 30% of patients.45,46 Because of the global burden of
disability attributable to MDD,47 the search for improved under-
standing of biomarkers of therapeutic resistance to current first-line
treatment options is pressing.1,48 Our results provide fresh evidence
that patients with treatment-resistant depression have the most
abnormally increased CRP levels compared with both treatment-
responsive and currently untreated patients. To our knowledge, a spe-
cific relationship between CRP and monoaminergic antidepressant
drug treatment resistance has not been demonstrated previously,
although there is evidence both for increased proinflammatory cyto-
kine concentrations3,14,49 and for increased peripheral expression of
cytokine related genes12 in treatment-resistant depression. There is
also some evidence that baseline inflammatory markers may be
useful predictors of treatment response in MDD.50,51 In a rat
model of treatment-resistant depression, elevated CRP at baseline
Table 1 Demographic, clinical and high-sensitivity CRP data
Mean (95% CI)/n (%) Group test
Healthy
volunteers
n = 54
Treatment-
responsive MDD
n = 48
Treatment-
resistant MDD
n = 102a
Untreated
MDD n = 48 Statistic P value
Age, years 34.2 (32.3–36.2) 35.9 (33.6–38.3) 36.5 (35.1–38.0) 35.1 (32.6–37.6) F = 1.14 0.34
Gender, female 37 (68.5%) 32 (66.7%) 72 (70.6%) 31 (64.6%) L = 0.61 0.89
Education level 3.7 (3.4–4.0) 3.4 (3.1–3.7) 3.3 (3.1–3.5) 3.3 (3.0–3.6) K = 6.42 0.09
Smoking status
Never smoked 35 (64.8%) 34 (70.8%) 63 (61.8%) 33 (68.8%) L = 2.36 0.88
Current smoker 9 (16.7%) 6 (12.5%) 18 (17.7%) 5 (10.4%)
Ex-smoker 10 (18.5%) 8 (16.7%) 21 (20.6%) 10 (20.8%)
HAM-D total score 0.8 (0.5–1.1) 4.0 (3.2–4.8) 18.3 (17.5–19.0) 20.5 (19.6–21.4) F = 615.0 <0.001
Number of failed antidepressant drug treatments
(lifetime)
N/A 1.1 (0.7–1.6) 2.7 (2.4–3.0) 1.8 (1.2–2.3) K = 38.0 <0.001
BMI, kg/m2 25.5 (23.9–27.1) 27.8 (26.2–29.5) 27.6 (26.5–28.7) 26.4 (24.7–28.0) K = 4.85 0.18
CRP, mg/L 1.3 (0.9–1.6) 2.1 (1.5–2.8) 3.1 (2.1–4.2) 2.50 (1.3–3.7) K = 10.72 0.01
CRP>3 mg/L 4 (7.4%) 11 (22.9%) 26 (25.5%) 14 (29.2%) L = 10.50 0.015
Log10 CRP −0.1 (−0.2 to 0.0) 0.1 (0.0–0.3) 0.2 (0.1–0.3) 0.0 (−0.1 to 0.2) F = 3.57 0.015
BMI-corrected CRP −0.1 (−0.3 to 0.0) 0.0 (−0.1 to 0.1) 0.1 (0.0–0.2) 0.0 (−0.2 to 0.0) F = 2.67 0.048
Cohen’s d for case–control difference in BMI-
corrected CRP
0.29 0.47 0.18
Estimated sample size (n; case and control) for 80%
power to detect difference in BMI-corrected CRP
188 73 486
BMI, body mass index; CRP, C-reactive protein; F, one-way analysis of variance; HAM-D, Hamilton Rating Scale for Depression; K, Kruskal–Wallis test; L, likelihood ratio; MDD, major
depressive disorder.
a. The majority of treatment-resistant patients were taking selective serotonin reuptake inhibitors (70%) with smaller numbers exposed to noradrenergic and specific serotonergic reuptake
inhibitors (15%), mixed reuptake inhibitors (25%), tricyclic antidepressants (4%), mood stabilisers (4%) and dopamine receptor antagonists (3%). Treatment-responsive patients were likewise
predominantly treated with selective serotonin reuptake inhibitors (85%), followed by mixed reuptake inhibitors (25%), noradrenergic and specific serotonergic reuptake inhibitors (11%) or
tricyclic antidepressants (4%). All treatment-resistant patients were taking at least one conventional antidepressant monoaminergic drug.
Chamberlain et al
14
Downloaded from https://www.cambridge.org/core. 19 Jun 2020 at 12:40:43, subject to the Cambridge Core terms of use.
differentiated responders from non-responders to ketamine, an N-
methyl-D-aspartate receptor antagonist with anti-inflammatory and
antidepressant effects.52 At a cellular level, neurons, microglia and
macrophages respond to inflammatory challenges by activatingmeta-
bolic pathways that reduce the synaptic availability of serotonin and
catalyse the conversion of tryptophan to kynurenine and its puta-
tively neurotoxic, glutamatergic agonist metabolites.15,53–55 These
effects of inflammation on serotonin transport and tryptophan
metabolismmay constitute amechanism bywhich peripheral inflam-
mation is associated with lack of therapeutic response to selective
serotonin reuptake inhibitors.56
Clinical phenotypes predictive of increased CRP in
depression
Obesity and its cardiovascular sequelae have been repeatedly asso-
ciated with increased CRP.43,57,58 In this study, which excluded
patients with a lifetime history of medical disorders including
atherosclerosis and diabetes, we confirmed that higher BMI was
strongly associated with higher CRP levels. One mechanistic explan-
ation is that macrophages constitute up to 60% of cells in adipose
tissue and can release large amounts of IL-6, which is a key driver
of CRP synthesis.59 Therefore, it is not surprising that inflammation
(CRP) and obesity (BMI) were related herein; however, we do not
consider that this association trivially accounts for increased CRP
in treatment-resistant depression. The groups did not differ signifi-
cantly in baseline BMI and the case–control difference remained sig-
nificant for the treatment-resistant patients even after statistical
regression to control for individual differences in BMI.
Of all the depressive symptoms measured, so-called vegetative
symptoms (psychomotor retardation, insomnia, difficulty getting
started, difficulty working) were more important in explaining
higher CRP. These findings are consistent with prior reports that
somatic but not cognitive symptoms of depression were associated
with increased CRP.60 Vegetative symptoms of depression are akin
to the illness or sickness behaviour that has been repeatedly
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demonstrated in animal models and experimental medicine
studies of humans exposed to acute proinflammatory chal-
lenge.2,61 We also found evidence that state anxiety was related
with CRP, which is compatible with prior data linking acute endo-
toxin exposure to anxious and depressive states in healthy
volunteers.62
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It is established that childhood trauma increases risk of later
mental health disorders, including depression.63 In a meta-analysis,
individuals exposed to childhood trauma had significantly elevated
levels of CRP in adulthood, albeit with a small effect size (Fisher’s Z
= 0.10).64 In a longitudinal study of female adolescents at risk of
depression, childhood adversity was found to promote subsequent
clustering of depression and inflammation.65 These results are com-
patible with our findings that feeling unloved in childhood and
wanting to change one’s family in childhood were significantly cor-
related with higher CRP in adults.
Methodological issues
Because of the case–control design, between-group differences in
CRP could theoretically be confounded by other factors influencing
peripheral inflammation. However, we excluded patients with
inflammatory disorders or anti-inflammatory drug treatment, and
the groups did not differ on demographic characteristics. The lack
of statistically significant case–control differences in BMI-corrected
CRP for the comparisons between healthy volunteers and the treat-
ment-responsive and untreated MDD groups could theoretically
reflect the smaller sizes of these groups compared with the treat-
ment-resistant MDD group. However, power calculations indicated
that the case–control differences in BMI-corrected CRP would
probably not have been significant even if the treatment-responsive
group had the same size as the resistant group (Table 1). Although
the untreated MDD group had not received antidepressant treat-
ment for at least six weeks, the majority (n = 28, 58.3%) had received
at least one such treatment in the past (the average number of his-
torically failed treatments in this group was 1.8). As such, this group
had some degree of heterogeneity, including both treatment-naïve
individuals and those who would have been expected to be treat-
ment-resistant if currently medicated. Treatment resistance was
defined by inadequate response to the current drug treatment
whereas some other criteria for treatment resistance stipulate a
failed response to at least two drugs of different mechanisms of
action. There are multiple definitions of treatment resistance used
in the field; our choice is widely used. The study was not planned
or powered to test differences in CRP between subgroups defined
by dose or type of current antidepressant medication. We did not
find that CRP differed significantly as a function of antidepressant
medication class, nor as a function of total number of previous
failed treatments (as measured by the ATRQ). A limitation in asses-
sing prior medications was the use of retrospective self-report, albeit
based on a comprehensive structured instrument completed by an
interviewer. The sample was recruited from the UK population,
which is known to differ from the USA and other populations in
terms of BMI and other factors that can influence the numerical dis-
tribution of CRP, and this may mitigate generalisability of our
results, as would our exclusion of people with inflammatory disor-
ders. Finally, CRP is only one of manymarkers of peripheral inflam-
mation that have been or could be linked to depression. Although
these data demonstrate that CRP is robustly associated with treat-
ment-resistant depression, we do not claim that CRP is necessarily
the best of all possible peripheral blood biomarkers of treatment-
resistant depression.
Conclusions
MDD is associated with increased CRP compared with healthy
volunteers and the case–control difference appears higher in treat-
ment-resistant depression. Increased CRP and treatment resistance
were also associated with other aspects of clinical heterogeneity in
depression including obesity, vegetative symptoms of fatigue and
sleep disturbance, state anxiety and a history of childhood adversity.
We suggest there may be a clinically and immunologically
diagnosable subsyndrome of ‘inflamed depression’ comprising the
patients with MDD most likely to benefit therapeutically from
second-line treatment with anti-inflammatory drugs.36
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psychiatry
in history
Charles Lloyd Tuckey and the “new hypnotism”
Gordon D. L. Bates
The second coming of medical hypnotism
At the end of 1919, a distinguished group of Edwardian physicians, scientists and other notables petitioned the British Prime
Minister for a civil list pension for one of their colleagues who had fallen on ‘straightened circumstances’ as a result of illness.
The unlikely subject of their lobbying was a hypnotist: Charles Lloyd Tuckey, a member of the Medico-Psychological Association
(the forerunner to the Royal College of Psychiatrists), who could no longer practice because of cancer and paralysis. The cor-
respondence can be found in the records of themysterious Bounty Fund in the National Archive at Kew (PROT1/12460 C677293).
The campaigners or memorialists, as they described themselves, included the renowned Canadian physician, William Osler, the
eminent Great War psychiatrist, F. W. Myers, the parliamentarian, Gerald Balfour and two physicists and fellows of the Royal
Society, Oliver Lodge and William Barrett. They argued that Lloyd Tuckey merited a pension because of his contribution to soci-
ety in bringing medical hypnotism to the UK in the 1890s. They praised his ‘courage and single-mindedness’ in bringing the tech-
nology from France when the prejudices against ‘animal-magnetism’ or mesmerism were still very prevalent. By the end of the
century, the trance state induced bymesmerismwas better known as an essential component ofmagic shows or spiritualism. In
the letter, they invoke, but do not directly mention, the controversial figure of John Elliotson, the founder of University College
Hospital and populariser of the use of the stethoscope, whose medical career was destroyed by his advocacy of mesmerism in
the 1840s.
Charles Lloyd Tuckey was the author of Psycho-Therapeutics: or, Treatment by Hypnotism and Suggestion, the first English lan-
guage textbook on medical hypnotism that ran to seven editions between 1889 and 1921. According to his contemporaries and
obituary writers, he was a charismatic and popular speaker who toured the local groups of the British Medical Association
across the UK, demonstrating and lecturing on the healing applications of the trance state. Across themedical press and gentle-
man’s journals such as ‘The Nineteenth Century’, hemade the case for its therapeutic use by themedical profession and restric-
tions to its trivial use in popular spiritualist seances and by stagemagicians. In the 1890s, he was engaged in a very public dispute
in both medical and lay journals with the editor of the British Medical Journal, Ernest Hart whose opposition to medical hypnosis
was as forceful as his other campaigns against insanitary conditions and the anti-vaccination lobby.
The last paragraph of the letter to the Prime Minister makes a claim that will surprise many: ‘Dr Tuckey’s work has prepared the
way for the recent great increase of the practice of psycho-therapeutics, a branch of medicine which, after long neglect in this
country, is generally recognised as one of the first importance and destined to undergo great further development in the near
future’. Whereas most historians and psychiatrists will know that the massive number of psychological casualties caused by the
First World War was responsible for a change in both the public awareness and recognition of mental illness, fewer may be
aware of the direct lineage of talking therapies from hypnosis. The case for this genealogy was first made by the medical his-
torian and psychiatrist Henri Ellenberger in his classic monograph, The Discovery of the Unconscious, first published in 1970.
Despite this, the importance of hypnosis is still not widely appreciated as a result of the hagiographic Freudian histories of
dynamic psychology that place Freud as the originator of psychotherapies and ideas of the unconscious. In fact, it can be rea-
sonably claimed that by using it in his book title, Lloyd Tuckey established the term psycho-therapeutics in the UK, a good two
decades before Freud’s work appeared in English translation.
Readers will be pleased to know that this early pioneer of psychological therapies was rewardedwith a pension of £200 and lived
for a further 5 years. Tellingly, he could not be given a civil pension by the Department of Health as his contributions were con-
sidered ‘not scientific’, a recurring criticism of hypnosis. However, David Lloyd George did see fit to provide him with a pension
from the Royal Bounty Fund, a secret unaccountable trust that only the Prime Minister could award without public scrutiny.
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